Taurine 7 pp 359-368 | Cite as

The Effects of Taurine, Taurine Homologs and Hypotaurine on Cell and Membrane Antioxidative System Alterations Caused by Type 2 Diabetes in Rat Erythrocytes

  • Davekanand Gossai
  • Cesar A. Lau-Cam
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 643)


This study compared taurine, aminomethanesulfonic acid, homotaurine and hypotaurine for the ability to modify indices of oxidative stress and membrane damage associated with type 2 diabetes. In the study, male Goto-Kakizaki and Wistar-Kyoto rats were allowed free access to a high fat and normal diet, respectively, for 9 weeks. At the end of week 8, half of the animals in each group received a daily intraperitoneal dose of a sulfur compound (0.612 M/kg) for 5 days and, 24 hr after the last treatment, blood samples were withdrawn by cardiac puncture to obtain plasma and erythrocyte fractions for biochemical analyses. Relative to control values, taurine and its congeners reduced membrane damage, the formation of intracellular malondialdehyde and oxidized glutathione, and the decreases in reduced glutathione and antioxidative enzyme activities in diabetic erythrocytes. Except for a few isolated instances, all test compounds were equiprotective.


Sulfur Compound Vanadyl Sulfate Normal RBCs Exogenous Oxidant Diabetic Erythrocyte 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aebi H (1984) Catalase in vitro. Methods Enzymol 105:121–126PubMedCrossRefGoogle Scholar
  2. Aruoma OI, Halliwell B, Hoey BM, Butler J (1988) The antioxidant action of taurine, hypotaurine and their metabolic precursors Biochem J 256:251–255Google Scholar
  3. Baynes JW, Thorpe SR (1999) Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 48:1–9PubMedCrossRefGoogle Scholar
  4. Beard KM, Shangari N, Wu B, O’Brien PJ (2003) Metabolism, not autoxidation plays a role in α-oxoaldehyde- and reducing sugar-induced erythrocyte GSH depletion: relevance for diabetes mellitus. Mol Cell Biochem 252:331–338PubMedCrossRefGoogle Scholar
  5. Buege JA, Aust SD (1978) Microsomal lipid peroxidation. Methods Enzymol 52:302–310PubMedCrossRefGoogle Scholar
  6. Ceriello A (2003) New insights on oxidative stress and diabetic complications may lead to a “causal” antioxidant therapy. Diabetes Care 26:1589–1596PubMedCrossRefGoogle Scholar
  7. Da Ros R, Assaloni R, Ceriello A (2004) Antioxidant therapy in diabetic complications:what is new? Curr Vasc Pharmacol 2:335–341PubMedCrossRefGoogle Scholar
  8. Donma O, Yorulmaz E, Pekel H, Suyugul N (2002) Blood and lens lipid peroxidation and antioxidant status in normal individuals, senile and diabetic cataractous patients. Curr Eye Res 25:9–16PubMedCrossRefGoogle Scholar
  9. Djordjevic A, Spasic S, Jovanovic-Galovic A, Djordjevic R, Grubor-Lajsic G (2004) Oxidative stress in diabetic pregnancy: SOD, CAT and GSH-Px activity and lipid peroxidation. J Matern Fetal Neonatal Med 16:367–372PubMedCrossRefGoogle Scholar
  10. Evans JL (2007) Antioxidants: do they have a role in the treatment of insulin resistance? Indian J Med Res 125:355–372PubMedGoogle Scholar
  11. Fellman JH, Roth ES (1985) The biological oxidation of hypotaurine to taurine: hypotaurine as an antioxidant. In: Oja SS, Ahtee L, Kontro P, Paasonen MK (eds) Taurine: biological actions and clinical perspectives, Alan R. Liss, New York, pp 71–82Google Scholar
  12. Flohé L, Günzler WA (1984) Assays of glutathione peroxidase. Methods Enzymol 105:114–121PubMedCrossRefGoogle Scholar
  13. Gallou G, Ruelland A, Campion L, Maugendre D, Le Moullec N, Legras B, Allannic H, Cloarec L (1994) Increase in thiobarbituric acid-reactive substances and vascular complications in type 2 diabetes mellitus Diabetes Metab 20:258–264Google Scholar
  14. Goodman HO, Shihabi ZK (1990) Supplemental taurine in diabetic rats: effects on plasma glucose and triglycerides. Biochem Med Metab Biol 43:1–9PubMedCrossRefGoogle Scholar
  15. Gürler B, Vural H, Yilmaz N, Oguz H, Satici A, Aksoy N (2000) The role of oxidative stress in diabetic retinopathy. Eye 14 (Pt 5):730–735PubMedGoogle Scholar
  16. Hissin PJ, Hilf R (1976) A fluorometric method for determination of oxidized and reduced glutathione in tissues. Anal Biochem 74:214–226PubMedCrossRefGoogle Scholar
  17. Huxtable RJ, Sebring LA (1986) Towards a unifying theory for the actions of taurine. Trends Pharmacol Sci 7:481–485CrossRefGoogle Scholar
  18. Huxtable RJ (1992) Physiological actions of taurine. Pharmacol Rev 72:101–163Google Scholar
  19. Kaneto H, Nakatani Y, Kawamori D, Miyatsuka T, Matsuoka T (2004) Involvement of oxidative stress and the JNK pathway in glucose toxicity. Rev Diabet Stud 1:165–174PubMedCrossRefGoogle Scholar
  20. Kesavulu MM, Giri R, Kameswara R.B, Apparao C (2000) Lipid peroxidation and antioxidant enzyme levels in type 2 diabetics with microvascular complications. Diabetes Metab 26:387–392PubMedGoogle Scholar
  21. Kulakowski EC, Maturo J (1984) Hypoglycemic properties of taurine: not mediated by enhanced insulin release. Biochem Pharmacol 33:2835–2838PubMedCrossRefGoogle Scholar
  22. Maiese K, Morhan SD, Chong ZZ (2007) Oxidative stress biology and cell injury during type 1 and type 2 diabetes mellitus. Curr Neurovasc Res 4:63–71PubMedCrossRefGoogle Scholar
  23. Memisogullari R, Taysi S, Bakan E, Capoglu I (2003) Antioxidant status and lipid peroxidation in type II diabetes mellitus. Cell Biochem Funct 21:291–296PubMedCrossRefGoogle Scholar
  24. Misra HP, Fridovich I (1972) The role of superoxide anion in the autoxidation of epinephrine and a simple assay for superoxide dismutase. J Biol Chem 247:3170–3175PubMedGoogle Scholar
  25. Ogasawara M, Nakamura T, Koyama I, Nemoto M, Yoshida T (1994) Reactivity of taurine with aldehydes and its physiological role. In: Huxtable R, Michalk DV (eds) Taurine in health and disease, Plenum Press, New York, pp 71–78Google Scholar
  26. Pitari G,Dupre S, Sprinto A, Antoni G (2000) Hypotaurine protection on cell damage by singlet oxygen. In: Della Corte L, Huxtable RJ, Sgaragli G, Tipton KF (eds) Taurine 4: taurine and excitable tissues, Kluwer Academic/Plenum Publishers, New York, pp 157–162Google Scholar
  27. Pokhrel KP, Lau-Cam C.A (2000) In vitro and in vivo effects of taurine and structurally related sulfur-containing compounds against phenylhydrazine-induced oxidative damage to erythrocytes. In: Della Corte L, Huxtable RJ, Sgaragli G, Tipton KF (eds) Taurine 4: taurine and excitable tissues, Kluwer Academic/Plenum Publishers, New York, pp 503–522Google Scholar
  28. Schaffer SW, Azuma J (1992) Myocardial physiological effects of taurine and their significance. In: Lombardini JB, Schaffer SW, Azuma J (eds) Taurine: nutritional value and mechanisms of action, Plenum Press, New York, pp 105–120Google Scholar
  29. Tadolini B, Pintus G, Pinna GG, Bennardini F, Franconi F (1995) Effects of taurine and hypotaurine on lipid peroxidation. Biochem Biophys Res Commun 213:820–826PubMedCrossRefGoogle Scholar
  30. Tas S, Sarandol, E, Ayvalik SZ, Serdar Z, Dirican M (2007) Vanadyl sulfate, taurine, and combined vanadyl sulfate and taurine treatments in diabetic rats: effects on the oxidative and antioxidative systems. Arch Med Res 38:276–283PubMedCrossRefGoogle Scholar
  31. Trachtman H, Futterweit D, Maesaka J, Ma C, Valderrama E, Fuchs A, Tarectecan AA, Rao PS, Sturman JA, Boles TH et al. (1995) Taurine ameliorates chronic streptozocin-induced diabetic nephropathy in rats Am J Physiol 269:F429–F438PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • Davekanand Gossai
    • 1
  • Cesar A. Lau-Cam
  1. 1.Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health ProfessionsSt. John’s UniversityJamaicaUSA

Personalised recommendations